NCT05988697 is a clinical trial of Combind asprin with Trametinib and Dabrafenib in NSCLC, sponsored by Daping Hospital and the Research Institute of Surgery of the Third Military Medical University.

What drugs are being tested in NCT05988697?

Interventions in NCT05988697: Combind asprin with Trametinib and Dabrafenib.

What condition does NCT05988697 study?

NCT05988697 studies NSCLC, BRAF V600E Mutation, Advanced Cancer, Stage IIIB NSCLC, Stage IV NSCLC.

Is NCT05988697 still recruiting?

NCT05988697 is currently not yet recruiting. Last updated 12 October 2023.

Last reviewed 2023-10-12 · How we verify

NCT05988697

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Evaluate the Efficacy and Safety of Aspirin in Combination With Trametinib and Dabrafenib

Not yet recruiting Last updated 12 October 2023

What this trial tests

trial testing Combind asprin with Trametinib and Dabrafenib in NSCLC in 36 participants. Not yet recruiting.

Timeline

1 November 2023

Primary endpoint
1 September 2026

1 April 2027

Quick facts

Lead sponsor	Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
Status	Not yet recruiting
Study type	OBSERVATIONAL
Enrollment	36
Start date	1 November 2023
Primary completion	1 September 2026
Estimated completion	1 April 2027

Drugs / interventions tested

Combind asprin with Trametinib and Dabrafenib — full drug profile →

Conditions studied

NSCLC — all drugs for NSCLC →
BRAF V600E Mutation — all drugs for BRAF V600E Mutation →
Advanced Cancer — all drugs for Advanced Cancer →
Stage IIIB NSCLC — all drugs for Stage IIIB NSCLC →

Sponsor

Daping Hospital and the Research Institute of Surgery of the Third Military Medical University

Who can join

Adults 18 to 75, any sex, with NSCLC or BRAF V600E Mutation. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to observe the safety and efficacy of Aspirin combined with Trametinib and Dalafenib in the treatment of advanced BRAF V600E mutated non-small cell lung cancer (NSCLC)

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for NSCLC

Currently open trials in the same condition.

NCT07479277 — Progel Platinum for Air Leak Reduction After VATS Lobectomy for NSCLC · NA · recruiting
NCT07323732 — A Study of BIO 300 and Thoracic Radiation Therapy in People With Non-Small Cell Lung Cancer and Interstitial Lung Diseas · Phase 2 · recruiting
NCT07274813 — A Phase I Study to Evaluate the Safety, Tolerability, and PK of HLX37 in Advanced/Metastatic Solid Tumors · EARLY_PHASE1 · recruiting
NCT07325864 — Molecular Phenotyping of Primitive Lung Cancer and Metastatic Site · recruiting
NCT07169552 — HC010 in First-line PD-L1 Positive Advanced NSCLC Patients · Phase 2 · recruiting

Other Daping Hospital and the Research Institute of Surgery of the Third Military Medical University trials

Trials by the same sponsor.

NCT07468630 — Tolecizumab Plus Chemoimmunotherapy for pMMR/MSS Locally Advanced Colon Adenocarcinoma · Phase 2 · recruiting
NCT07467590 — Combination of High and Low-Dose Radiotherapy With Immune Therapy and TKI in Advanced Colorectal Cancer: A Phase II Stud · Phase 2 · not yet recruiting
NCT07459192 — Clinical Study of 68Ga-DOTA-BLP PET Imaging in Noninvasive Diagnosis of Malignant Tumors · not yet recruiting
NCT07459179 — Clinical Study on the Application of PET Probes Targeting DDR2 in the Diagnosis of Interstitial Lung Disease With Cognit · not yet recruiting
NCT07459205 — Clinical Application of 68Ga-1A12 PET in Fibrosis-related Diseases · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05988697 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
Last refreshed: 12 October 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05988697.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing